Abstract
We report insights from ten weeks of collaborative COVID-19 forecasting for Germany and Poland (12 October – 19 December 2020). The study period covers the onset of the second wave in both countries, with tightening non-pharmaceutical interventions (NPIs) and subsequently a decay (Poland) or plateau and renewed increase (Germany) in reported cases. Thirteen independent teams provided probabilistic real-time forecasts of COVID-19 cases and deaths. These were reported for lead times of one to four weeks, with evaluation focused on one- and two-week horizons, which are less affected by changing NPIs. Heterogeneity between forecasts was considerable both in terms of point predictions and forecast spread. Ensemble forecasts showed good relative performance, in particular in terms of coverage, but did not clearly dominate single-model predictions. The study was preregistered and will be followed up in future phases of the pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work of Johannes Bracher was supported by the Helmholtz Foundation via the SIMCARD Information and Data Science Pilot Project. Sangeeta Bhatia acknowledges support from the Wellcome Trust (219415). Nikos I. Bosse acknowledges funding by the Health Protection Research Unit (grant code NIHR200908). Sebastian Funk and Sam Abbott acknowledge support from the Wellcome Trust (grant no. 20210758/Z/18/Z). The work of Ajitesh Srivastava was supported by National Science Foundation Award No. 2027007 (RAPID). Tilmann Gneiting and Daniel Wolffram are grateful for support by the Klaus Tschira Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Purely observational study, no ethics approval required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Updated authorship list including authors not included in first version due to pending clearance procedures.
Reproducibility / data availability
All data used in this article are publicly available at https://github.com/KITmetricslab/covid19-forecast-hub-de. Forecasts can be visualized interactively at https://github.com/KITmetricslab/covid19-forecast-hub-de. Codes to reproduce figures and tables are available at https://github.com/KITmetricslab/analyses_de_pl.
